- Home
- SGA vs HLVX Comparison
SGA vs HLVX Comparison
Compare SGA & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- HLVX
- Stock Information
- Founded
- SGA 1986
- HLVX 2020
- Country
- SGA United States
- HLVX United States
- Employees
- SGA N/A
- HLVX N/A
- Industry
- SGA Broadcasting
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- HLVX Health Care
- Exchange
- SGA Nasdaq
- HLVX Nasdaq
- Market Cap
- SGA 74.2M
- HLVX 83.7M
- IPO Year
- SGA 1992
- HLVX 2022
- Fundamental
- Price
- SGA $12.25
- HLVX $1.87
- Analyst Decision
- SGA
- HLVX Hold
- Analyst Count
- SGA 0
- HLVX 5
- Target Price
- SGA N/A
- HLVX $2.33
- AVG Volume (30 Days)
- SGA 4.1K
- HLVX 219.8K
- Earning Date
- SGA 05-08-2025
- HLVX 05-08-2025
- Dividend Yield
- SGA 8.16%
- HLVX N/A
- EPS Growth
- SGA N/A
- HLVX N/A
- EPS
- SGA 0.55
- HLVX N/A
- Revenue
- SGA $111,837,000.00
- HLVX N/A
- Revenue This Year
- SGA N/A
- HLVX N/A
- Revenue Next Year
- SGA $5.04
- HLVX N/A
- P/E Ratio
- SGA $22.43
- HLVX N/A
- Revenue Growth
- SGA N/A
- HLVX N/A
- 52 Week Low
- SGA $10.75
- HLVX $1.34
- 52 Week High
- SGA $18.19
- HLVX $15.60
- Technical
- Relative Strength Index (RSI)
- SGA 55.44
- HLVX 51.02
- Support Level
- SGA $11.88
- HLVX $1.82
- Resistance Level
- SGA $12.45
- HLVX $1.89
- Average True Range (ATR)
- SGA 0.45
- HLVX 0.07
- MACD
- SGA 0.02
- HLVX -0.02
- Stochastic Oscillator
- SGA 71.43
- HLVX 22.73
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.